AIDS

Papers
(The H4-Index of AIDS is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The need to avert emergent resistance to dolutegravir in children and adolescents with HIV60
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy56
Strategies for managing weight gain associated with antiretroviral therapy: switch or add?48
Elevated stress-responsive biomarkers are associated with HIV acquisition in young women in rural South Africa48
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine48
Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies37
A new frontier in HIV care: the predictive power of renal biomarkers on heart health37
Real world use of dolutegravir two drug regimens36
Cerebral toxoplasmosis in the twenty-first century35
Keeping up with Streptococcus pneumoniae in children living with HIV: Erratum31
Reduced bone density accrual among peripubertal boys with HIV in Zimbabwe: Erratum30
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin29
Multisector global collaboration to advance the inclusion of pregnant and lactating people in HIV prevention research29
HIV-1 gp120 amplifies astrocyte elevated gene-1 activity to compromise the integrity of the outer blood–retinal barrier26
Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France26
Applying rigorous real-world evidence methodology in HIV medicine: is more evidence needed with long-acting cabotegravir/rilpivirine?25
Trends in population HIV viral suppression: a longitudinal analysis25
Associations between social determinants of health and comorbidity and multimorbidity in people of black ethnicities with HIV24
Gut microbiota and plasma metabolites associated with bone mineral density in women with or at risk of HIV infection24
Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV23
Virtual case management: a differentiated approach to HIV prevention, treatment, and care23
Life expectancy of people with HIV on antiretroviral therapy in Spain23
Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men22
Quantifying missed opportunities for tuberculosis among people with HIV in the US President's Emergency Plan for AIDS Relief22
Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort22
0.64996600151062